Log In
Print
BCIQ
Print
Print this Print this
 

SynGEM

  Manage Alerts
Collapse Summary General Information
Company Mucosis B.V.
DescriptionRespiratory synctial virus vaccine comprised of bacterium-like-particle (BLP) based Mimopath technology carrying trimeric Fusion proteins
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine: Viral vaccine
Latest Stage of DevelopmentPreclinical
Standard IndicationRespiratory syncytial virus (RSV)
Indication DetailsPrevnt respiratory syncytial virus (RSV) infections
Regulatory Designation

Partner

Changchun BCHT Biotechnology Co.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today